Kim Youlim, An Tai Joon, Park Yong Bum, Kim Kyungjoo, Cho Do Yeon, Rhee Chin Kook, Yoo Kwang-Ha
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Republic of Korea.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea.
Tuberc Respir Dis (Seoul). 2022 Jan;85(1):74-79. doi: 10.4046/trd.2021.0121. Epub 2021 Nov 15.
The effect of underlying chronic obstructive pulmonary disease (COPD) on coronavirus disease 2019 (COVID-19) during a pandemic is controversial. The purpose of this study was to examine the prognosis of COVID-19 according to the underlying COPD.
COVID-19 patients were assessed using nationwide health insurance data. Comorbidities were evaluated using the modified Charlson Comorbidity Index (mCCI) which excluded COPD from conventional CCI scores. Baseline characteristics were assessed. Univariable and multiple logistic and linear regression analyses were performed to determine effects of variables on clinical outcomes. Ages, sex, mCCI, socioeconomic status, and underlying COPD were selected as variables.
COPD patients showed older age (71.3±11.6 years vs. 47.7±19.1 years, p<0.001), higher mCCI (2.6±1.9 vs. 0.8±1.3, p<0.001), and higher mortality (22.9% vs. 3.2%, p<0.001) than non-COPD patients. The intensive care unit admission rate and hospital length of stay were not significantly different between the two groups. All variables were associated with mortality in univariate analysis. However, underlying COPD was not associated with mortality unlike other variables in the adjusted analysis. Older age (odds ratio [OR], 1.12; 95% confidence interval [CI], 1.11-1.14; p<0.001), male sex (OR, 2.29; 95% CI, 1.67-3.12; p<0.001), higher mCCI (OR, 1.30; 95% CI, 1.20-1.41; p<0.001), and medical aid insurance (OR, 1.55; 95% CI, 1.03-2.32; p=0.035) were associated with mortality.
Underlying COPD is not associated with a poor prognosis of COVID-19.
在大流行期间,潜在的慢性阻塞性肺疾病(COPD)对2019冠状病毒病(COVID-19)的影响存在争议。本研究的目的是根据潜在的COPD情况来研究COVID-19的预后。
使用全国健康保险数据对COVID-19患者进行评估。使用改良的Charlson合并症指数(mCCI)评估合并症,该指数从传统的CCI评分中排除了COPD。评估基线特征。进行单变量和多变量逻辑回归及线性回归分析,以确定变量对临床结局的影响。选择年龄、性别、mCCI、社会经济地位和潜在的COPD作为变量。
与非COPD患者相比,COPD患者年龄更大(71.3±11.6岁 vs. 47.7±19.1岁,p<0.001),mCCI更高(2.6±1.9 vs. 0.8±1.3,p<0.001),死亡率更高(22.9% vs. 3.2%,p<0.001)。两组的重症监护病房入住率和住院时间无显著差异。在单变量分析中,所有变量均与死亡率相关。然而,在调整分析中,与其他变量不同,潜在的COPD与死亡率无关。年龄较大(比值比[OR],1.12;95%置信区间[CI],1.11-1.14;p<0.001)、男性(OR,2.29;95%CI,1.67-3.12;p<0.001)、mCCI较高(OR,1.30;95%CI,1.20-1.41;p<0.001)和医疗救助保险(OR,1.55;95%CI,1.03-2.32;p=0.035)与死亡率相关。
潜在的COPD与COVID-19的不良预后无关。